JP Morgan Chase
CBMG

JP Morgan Chase’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

JP Morgan Chase’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-174,264
Closed -$3.2M – 6553
2020
Q4 		$3.2M Buy
174,264
+74,279
+74% +$1.35M ﹤0.01% 3151
2020
Q3 		$1.83M Buy
99,985
+17,431
+21% +$293K ﹤0.01% 3293
2020
Q2 		$1.24M Buy
82,554
+25,852
+46% +$369K ﹤0.01% 3394
2020
Q1 		$896K Buy
56,702
+34,148
+151% +$552K ﹤0.01% 3465
2019
Q4 		$365K Buy
22,554
+18,582
+468% +$310K ﹤0.01% 4400
2019
Q3 		$59K Buy
3,972
+643
+19% +$8.67K ﹤0.01% 5110
2019
Q2 		$50K Buy
3,329
+498
+18% +$8.13K ﹤0.01% 5171
2019
Q1 		$49K Sell
2,831
-132
-4% -$2.4K ﹤0.01% 5147
2018
Q4 		$52K Buy
2,963
+271
+10% +$4.6K ﹤0.01% 5064
2018
Q3 		$49K Buy
2,692
+336
+14% +$6.89K ﹤0.01% 5203
2018
Q2 		$46K Buy
+2,356
New +$44.1K ﹤0.01% 5110

JP Morgan Chase's CBMG Position: Q1 2021 in Review

JP Morgan Chase sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 174,264 shares — an estimated $3.2M sold.

JP Morgan Chase first reported a position in CBMG in Q2 2018 and held it in 11 quarters. The position peaked at $3.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • JP Morgan Chase reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • JP Morgan Chase sold 174,264 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $3.2M.
  • JP Morgan Chase first reported a position in Cellular Biomedicine Group, Inc. in Q2 2018 and held it in 11 quarters.
  • JP Morgan Chase's Cellular Biomedicine Group, Inc. position peaked at $3.2M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.